Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
PINDOLOL CLOPAMIDE
Novartis Pharmaceuticals UK Ltd
PINDOLOL CLOPAMIDE
%v/v
Tablets
Withdrawn
2009-09-29
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT VISKALDIX 10mg/5mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10mg of pindolol and 5mg of clopamide. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Tablet. White, round, uncoated, flat, bevelled-edge tablets of 7 mm in diameter, having a single break-line and code 7 D on one side and branded ‘SANDOZ’ on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Mild to moderate hypertension. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS The recommended dose is one tablet daily to be taken in the morning. If the blood pressure is not satisfactorily controlled after 2 or 3 weeks, a second tablet may be given with the mid day meal. A maximum dose of 3 tablets daily may be taken if necessary. CHILDREN Not recommended. USE IN THE ELDERLY No evidence exists to suggest that the dosage or tolerability of VISKALDIX is directly affected by advanced age. However, because of the diuretic component, such patients should be carefully supervised as factors commonly associated with ageing, such as poor diet or impaired renal function may indirectly affect the dosage or tolerability. METHOD OF ADMINISTRATION Oral. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 30/06/2007_ _CRN 2038372_ _page number: 1_ 4.3 CONTRAINDICATIONS Untreated cardiac failure (see also precautions), sick sinus syndrome (including sino – atrial block), second and third degree heart block, Prinzmetal’s angina, untreated phaeochromocytoma, metabolic acidosis, pronounced bradycardia, cor pulmonale, refractory hypokalaemia, hyponatraemia, hypercalcaemia, Addison’s disease, severe renal or hepatic impairment and symptomatic hyperuri Read the complete document